Cargando…

Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain

BACKGROUND: Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study object...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz, Asuncion, Diez, Mercedes, Bleda, Maria Jose, Aldamiz, Mikel, Camafort, Miguel, Camino, Xabier, Cepeda, Concepcion, Costa, Asuncion, Ferrero, Oscar, Geijo, Paloma, Iribarren, Jose Antonio, Moreno, Santiago, Moreno, Maria Elena, Labarga, Pablo, Pinilla, Javier, Portu, Joseba, Pulido, Federico, Rosa, Carmen, Santamaría, Juan Miguel, Telenti, Mauricio, Trapiella, Luis, Trastoy, Monica, Viciana, Pompeyo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945350/
https://www.ncbi.nlm.nih.gov/pubmed/20840743
http://dx.doi.org/10.1186/1471-2334-10-267
_version_ 1782187213373571072
author Diaz, Asuncion
Diez, Mercedes
Bleda, Maria Jose
Aldamiz, Mikel
Camafort, Miguel
Camino, Xabier
Cepeda, Concepcion
Costa, Asuncion
Ferrero, Oscar
Geijo, Paloma
Iribarren, Jose Antonio
Moreno, Santiago
Moreno, Maria Elena
Labarga, Pablo
Pinilla, Javier
Portu, Joseba
Pulido, Federico
Rosa, Carmen
Santamaría, Juan Miguel
Telenti, Mauricio
Trapiella, Luis
Trastoy, Monica
Viciana, Pompeyo
author_facet Diaz, Asuncion
Diez, Mercedes
Bleda, Maria Jose
Aldamiz, Mikel
Camafort, Miguel
Camino, Xabier
Cepeda, Concepcion
Costa, Asuncion
Ferrero, Oscar
Geijo, Paloma
Iribarren, Jose Antonio
Moreno, Santiago
Moreno, Maria Elena
Labarga, Pablo
Pinilla, Javier
Portu, Joseba
Pulido, Federico
Rosa, Carmen
Santamaría, Juan Miguel
Telenti, Mauricio
Trapiella, Luis
Trastoy, Monica
Viciana, Pompeyo
author_sort Diaz, Asuncion
collection PubMed
description BACKGROUND: Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion. METHODS: Subjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI). RESULTS: A total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9). CONCLUSIONS: A minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed.
format Text
id pubmed-2945350
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29453502010-09-26 Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain Diaz, Asuncion Diez, Mercedes Bleda, Maria Jose Aldamiz, Mikel Camafort, Miguel Camino, Xabier Cepeda, Concepcion Costa, Asuncion Ferrero, Oscar Geijo, Paloma Iribarren, Jose Antonio Moreno, Santiago Moreno, Maria Elena Labarga, Pablo Pinilla, Javier Portu, Joseba Pulido, Federico Rosa, Carmen Santamaría, Juan Miguel Telenti, Mauricio Trapiella, Luis Trastoy, Monica Viciana, Pompeyo BMC Infect Dis Research Article BACKGROUND: Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion. METHODS: Subjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI). RESULTS: A total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9). CONCLUSIONS: A minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed. BioMed Central 2010-09-14 /pmc/articles/PMC2945350/ /pubmed/20840743 http://dx.doi.org/10.1186/1471-2334-10-267 Text en Copyright ©2010 Diaz et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Diaz, Asuncion
Diez, Mercedes
Bleda, Maria Jose
Aldamiz, Mikel
Camafort, Miguel
Camino, Xabier
Cepeda, Concepcion
Costa, Asuncion
Ferrero, Oscar
Geijo, Paloma
Iribarren, Jose Antonio
Moreno, Santiago
Moreno, Maria Elena
Labarga, Pablo
Pinilla, Javier
Portu, Joseba
Pulido, Federico
Rosa, Carmen
Santamaría, Juan Miguel
Telenti, Mauricio
Trapiella, Luis
Trastoy, Monica
Viciana, Pompeyo
Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
title Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
title_full Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
title_fullStr Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
title_full_unstemmed Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
title_short Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
title_sort eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of hiv-infected people in spain
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945350/
https://www.ncbi.nlm.nih.gov/pubmed/20840743
http://dx.doi.org/10.1186/1471-2334-10-267
work_keys_str_mv AT diazasuncion eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT diezmercedes eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT bledamariajose eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT aldamizmikel eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT camafortmiguel eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT caminoxabier eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT cepedaconcepcion eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT costaasuncion eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT ferrerooscar eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT geijopaloma eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT iribarrenjoseantonio eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT morenosantiago eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT morenomariaelena eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT labargapablo eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT pinillajavier eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT portujoseba eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT pulidofederico eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT rosacarmen eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT santamariajuanmiguel eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT telentimauricio eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT trapiellaluis eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT trastoymonica eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain
AT vicianapompeyo eligibilityforandoutcomeoftreatmentoflatenttuberculosisinfectioninacohortofhivinfectedpeopleinspain